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1. Introduction
Helicobacter pylori (H. pylori) is an important pathogen in human gastroenterology. H. pylori is
commonly acquired during early childhood and it is more common among people in devel‐
oping countries. Globally, over 50% of the population is infected with this bacteria, being
practically evenly distributed between the two genders, in spite of a few studies showing a
slight predisposition in males.
The clinical consequences of H. pylori infection in children are yet to be fully understood. H.
pylori infection in children differs from the same infection in adults, both in terms of the
percentage of infected individuals, symptoms, degree of complication towards peptic ulcer
disease or malignancy, the gastric areas affected, the degree of compliance to therapeutic
management or bacterial resistance to treatment.
2. Context
Helicobacter pylori (H. pylori) is a Gram - negative bacillus responsible for one of the most
commonly diagnosed infections, namely gastritis, in humans worldwide. [1]
In 1983 Robin Warren, an Australian pathologist, described an S-shaped bacteria for the first
time, that was found in the gastric mucosa. Together with Barry Marshall, they managed to
isolate thid micro-organism from biopsy samples taken during endoscopy, and called it
Campylobacter pyloridis, to be called H. pylori later on. [2]
Although the presence of bacteria in the stomach had been known as early as the 19th century,
these microbes were considered simply a consequence of gastric mucosa contamination from
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
food intake and not colonizing species in the true sense of the word. The current in thinking
had been so controversial from the very beginning, that, about 30 years later, when H. pylori
was discovered and proposed as the causative agent for gastritis and peptic ulcer disease, the
scientific community rejected and even ridiculed the new theory. Survival of microbes in the
acidic pH conditions of the stomach was considered impossible.
In one of the boldest scientific approaches of the last century, Barry Marshall self-administered
an H. pylori dose in 1984. Although the researcher physician expected to develop peptic ulcer
disease in the coming months, the symptoms emerged much sooner: only 3 days later, Marshall
displayed dizziness, halitosis and vomiting, and in another 8 days, pangastritis was diagnosed
endoscopically, meaning inflammation of a large areas of the stomach.
Shortly after the publication of results in Warren and Marshall’s research, H. pylori was also
detected in biopsy specimens taken during digestive endoscopy performed in children with
chronic gastritis and / or duodenal ulcers; at the same time, resolution of gastric pathology in
children was also demonstrated with bacterial eradication. [3] Overall, these discoveries have
demonstrated the important role of H. pylori in gastric pathology both in adults and children.
The discovery of H. pylori, the demonstration of causality between the infection and gastric
pathology and improvement of the bacteria eradication methodology increased the living
quality for a large number of patients. If, in the past, peptic ulcer disease surgery used to
be  one  of  the  most  common  forms  of  surgery  performed,  management  of  ulcers  by
eradication of H. pylori is so effective nowadays that very few patients require surgery. The
merit  of  Warren  and  Marshall’s  pioneering  research  was  awarded  the  Nobel  Prize  for
medicine in 2005.
Goals of current and future research of H. pylori equally require better understanding of
immune-pathogenics of gastric disease associated with H. pylori infection, clarification of
modes of transmission, as well as improving the safety and effectiveness of vaccines for
prevention of H. pylori infection.
Children  are  different  from adults  regarding  H.  pylori  infection,  in  terms  of  the  preva‐
lence  of  the  infection,  the  complication  rate,  the  almost  complete  absence  of  gastric
malignancy, age-specific issues, with diagnostic tests and medication as well as a higher
rate of resistance to antibiotics. The former and other differences as well can explain why
some of the recommendations for adults cannot be applied to children. [4]
3. Description of H. pylori
Phylogenetic classification of H. pylori is: Helicobacter genus, Helicobacteraceae family, Campy‐
lobacterales order, Proteobacteria subdivision.
H. pylori is a Gram - negative type bacterium, able to colonize the gastric mucosa in the majority
of the population in the context of very low pH and low partial pressure of oxygen (pO2). H.
pylori has a curved shape and is 2-4 microns long and 1 micron wide. It displays 2-6 flagella of
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about 3 microns in length, ensuring it high mobility. [5] Optimal development of this organism
requires reduced O2 pressure, high humidity, 37° C temperature and neutral pH. The metab‐
olism of the microbe can process glucose but not any other sugars.
The bacterium displays a  range of  extraordinary adaptations needed for  survival  in the
extreme conditions of the gastric environment. H. pylori is one of the most efficient animal
species, capable of degrading urea. The abundance of the urease enzyme allows rapid urea
hydrolysis  in  the  gastric  environment,  with release  of  bicarbonate  and ammonia,  which
neutralize the gastric pH and provide for the optimum conditions for bacterial life. At the
same time,  the  ammonia  generated  is  used in  the  metabolism of  the  bacterium for  the
synthesis  of  amino acids.  [6]  Initially,  the  urease  enzyme is  solely  localized in  the  cyto‐
plasm, however, in the case of exposure to acid in vivo, autolysis of the cell wall takes place
and release of the enzyme, which is subsequently fixed on the H. pylori surface. At the same
time, increased motility allows the bacterium to penetrate and become fixed in the layers
of the gastric mucosa. [7]
Outside the host organism, however, H. pylori is fragile and unable to survive when stored at
low and ultra-low temperatures as compared with other intestinal bacteria. Although healthy
individuals’ manner of infection of is not yet fully understood, it is assumed that transmission
is largely by direct contact of individuals and less by contaminated objects.
4. The rate of H. pylori infection
H. pylori infection global rate differs by region, ethnicity, age, and socio-economic level of the
population. The percentage of infected individuals is higher in disadvantaged socio-economic
categories and increases with age. Large infection percentages (about 80%) may be found in
Asian countries, in Eastern and South-Eastern Europe, in Latin America, whereas much
smaller percentages (about 40%) are characteristic to Western countries. [8-10]
Regardless of the geographic area analysed, one finds that H. pylori infection is usually
acquired in early childhood both in developed and developing countries.
5. Prevalence
Overall, about one third of the population is infected with H. pylori, and the frequency increases
with age.
In general, the prevalence is higher in developing countries, and the infection is contacted at
an early age. The incidence is 3-10% of the population every year in developing countries, as
compared to 0.5% in developed countries. [11]
The prevalence of H. pylori infection is not only lower in industrialized countries than in
developing countries, but the incidence of H. pylori infection, gastric cancer, peptic ulcer
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disease and related diseases are also declining. Worldwide, more than 1 billion people are
estimated to be infected with H. pylori. [4]
6. Possibility of transmission
H. pylori does not tolerate increased O2 partial pressure, high temperatures or nutrients poor
environments outside the host organism. In other words, H. pylori is excellently adapted to
gastric existing parameters, but it is a fragile organism, non-viable outside the host. One study
highlights the possibility for Helicobacter pylori infection from a water supply. For these reasons,
although the exact H. pylori mode of transmission is not completely understood, the type of
transmission is accepted by primarily direct contact of healthy individuals with an infected
person. Transmission of infection may also be the result of transport vectors.
H. pylori isolated strains are found more often in staff performing endoscopies than the general
population.
H. pylori has been isolated and cultivated from faeces, indicating the possibility of faecal-oral
transmission. Also, H. pylori was found in the oral cavity in both saliva and the plaque,
suggesting oral-oral transmission variant. Therefore, transmission of H. pylori can occur by
oral-oral, faecal-oral transmission or a combination thereof. [12]
Horizontal transmission is favoured by overcrowding found in densely populated human
communities. This version is the most likely in the case of infection transmission among family
members. Thus, children of H. pylori infected mothers run an 8 times higher risk of acquiring
the bacterium. [13]
7. Diagnosis of H. pylori
Correct diagnosis of H. pylori is possible through a wide range of working methods. However,
the opportunity to diagnose H. pylori and the working method chosen should be evaluated
according to the specificity of each case.
H. pylori infection generated symptoms is nonspecific, including abdominal pain, gastro-
oesophageal reflux with or without heartburn, halitosis, vomiting or hematemesis.
Because symptoms caused by H. pylori are general (nonspecific), the H. pylori infection may
overlap with another digestive or abdominally located disorder. Therefore, the primary
purpose of investigating gastrointestinal symptoms should be elucidating their real ethyology
and not just determining the presence of H. pylori infection. This consideration is especially
important in the case of H. pylori infection in children under the age of 12, because the latter
are unable to accurately describe the location, nature or intensity of their discomfort. [14]
Assessment of patients infected with H. pylori should pay particular attention to anorexia and
weight loss, pallor or laboratory tests to identify anaemia, vomiting, abdominal pain or pain
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associated with meals and night-time, as well as to any descriptions of gastrointestinal
haemorrhage.
In children suspected of H. pylori infection, history should include the following:
• Abominable pain nature, location, frequency, duration, severity, exacerbation and alleviat‐
ing factors;
• The intestinal transit and description of the stool;
• Appetite, diet, changes in weight;
• Halitosis, vomiting and description of the gastric material;
• Ulcer disease or gastrointestinal disorders (e.g. Crohn's disease) running in the family;
• Medications (on-prescription and OTC);
• Previous diagnostic tests and gastrointestinal tract specific therapy.
Physical examination of an asymptomatic H. pylori infected child usually ends in confusing
results. In children with chronic gastritis, duodenal and peptic ulcer, important findings
include epigastric tenderness or gastrointestinal bleeding (e.g., positive guaiac stools, tachy‐
cardia, pallor).
Children with peptic ulcer can develop complications (e.g., severe blood loss in the gastroin‐
testinal tract, perforation, obstruction) and may show signs of hemodynamic instability or
signs of acute abdomen. Children with long-term peptic ulcer caused by H. pylori may become
anaemic from undetected and asymptomatic chronic bleeding. In such children, the following
should be considered:
• The child’s overall appearance;
• Assessment of perfusion, paying special attention to the child’s mental status, heart rate,
pulse as well as refill of capillaries.
• Evaluation of the child’s skin as well as conjunctivae in order to check pallor.
• Careful cardiac and pulmonary scrutiny.
• Abdomen inspection, auscultation and palpating.
• Making a rectal exam and the guaiac test of the stool. [4]
For accurate diagnosis of H. pylori infection, several methods are available with varying
degrees of accuracy:
7.1. Histopathological methods
Isolation and cultivation of H. pylori in biopsy specimens taken during endoscopy is the golden
standard in diagnosing the infection. In addition, this method also has the advantage of
providing information about tissue pathology as caused by H. pylori infection. Since distribu‐
tion of H. pylori concentration on the gastric mucosa is not uniform but has rather the appear‐
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ance of distinct lower or higher concentration islands, taking at least 2 biopsies is
recommended, one of the gastric body and the other from the antrum. [15]
7.2. Breath analysis
Diagnosis of H. pylori infection may also be performed by breath analysis after oral adminis‐
tration of a urea solution. If the urea used is provided with a 13C- labelled carbon atom, this
isotope dosage can be performed, but the method is both very precise and demanding in terms
of the equipment involved. Alternatively, unmarked urea can be administered to qualitatively
detect the presence of H. pylori by identification of NH3 (ammonia) in the air expired. [4]
7.3. Immunological methods
H. pylori infection causes emergence of specific antibodies: anti - H. pylori antibodies (IgA and
IgG) in serum, blood, urine and / or saliva. Although cheap and fast, detection of these
antibodies is not relevant to assess the current status of infection or success of the eradication
therapy. Because of immunological memory, antibodies may persist for months and years even
in the host organism after eradication of the infection. [16-18]
7.4. Detection of antigens
Identification of H. pylori antigen in faeces is an accurate way of establishing the diagnosis, as
a non-invasive method and easier to apply in children than administration of urea solution or
endoscopy.
In addition, the method has the advantage that even after the passage of five days from sample
harvest, diagnosing H. pylori is as accurate. Thus, sampling of biological material can be
performed without the active participation of children and their visit to the medical centre, as
the sample may be dispatched by courier. [4]
Colonization of gastric mucosa by H. pylori does not automatically mean onset of the disease,
but the infection correlates with increased risk of infection during the onset of peptic ulcers
and gastric cancer. The materialization of this risk depends on a summation of factors related
to the genome of the bacterium, the host and environmental factors.[19]
A wide range of extra-gastrointestinal disorders are thought to be associated with H. pylori
infection, e.g. otitis media, upper respiratory tract infections, periodontitis, food allergies,
Sudden Infant Death Syndrome (SIDS). However, there is currently no convincing scientific
evidence regarding the causal relationship between H. pylori infection and such disorders.
Symptoms associated with H. pylori infection may be absent even in some cases where the
presence of H. pylori was proved by histological analysis. In other cases however, infection is
followed by the occurrence of peptic ulcer and its complications. The general pathology of H.
pylori includes phenomena such as dyspepsia and refractory anaemia. [15]
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8. Incriminatory factors
To determine their causal relationship with H. pylori infection, epidemiological studies have
addressed various factors such as a bacterial cause, the host, genetic and environmental factors.
Data are related to the spread of infection from person to person (e. g. dental plaque), but the
origin and the mode of transmission is incomplete known. [4]
H. pylori infection causes include the following:
• We can observe that the transmission of H. pylori is possible person to person.
Groups of infection are under observation, particularly within families of infected children.
Possible routes are faecal-oral, oral-oral and gastro-oral. Mother to child transmission has been
suggested in a study analysing DNA of H. pylori strains. [20] Studies have shown identical H.
pylori strains in mothers and their younger children. Maternal symptoms of nausea and
vomiting and pacifier use were associated with the risk of H. pylori infection in children.
Cervantes et al. participated a study performed at the US-Mexico border and they have shown
that a younger brother is 4 times more prone to H. pylori infection if the mother was H. pylori
infected, compared to an uninfected mother. Younger brothers are 8 times more likely to
acquire the infection if an older brother had persistent H. pylori infection. [13]
Absence or poor personal hygiene may also play a role. Increase in H. pylori infection may be
observed in developing countries, which may reflect the combined effects of poor living
conditions, poor hygiene and overcrowded cities.
The status of H. pylori infection in the United States, a comparatively higher socio-economic
setting, shows that the higher the social and economic level, the lower the incidence of H.
pylori infection, a finding that may reflect also the same factors as those mentioned in the case
of developing countries.
• In the clinical manifestations of H. pylori infection the bacterial factors may play an important
role. Patients infected with H. pylori may have two basic phenotypes reported the presence
or absence of cytotoxin vacuole.
Inflammation is more pronounced in people with cytotoxin - positive infection, confirmed at
endoscopy, than in those infected with H. pylori cytotoxin - negative.
As far as bacterial factors are involved, presence of two fundamental phenotypes has been
shown in H. pylori infected patients, i.e. vacuolating cytotoxin positive and negative, respec‐
tively. Endoscopy performed on cytotoxin-positive infected patients has proved inflammation
more marked than in patients where the cytotoxin was absent.[13]
The significance of host dependent factors has been demonstrated by such observations as the
fact that adults are less capable of solving acute infections than children.
A different such factor may be the presence of hypochlorhydria in the host, which allows
specific H. pylori colonization of the stomach.
In addition, H. pylori may only persist if the metaplastic epithelium of the stomach is atrophied.[4]
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• One study highlights the possibility for H. pylori infection from a water supply. [21]
• Transmission of infection may also be the result of transport vectors. [22]
• H. pylori isolated strains are found more often in staff performing endoscopies than the
general population.
9. Pathophysiology
H. pylori organisms are spiral Gram - negative bacteria, highly mobile due to their multiple
unipolar flagella. They are microaerophilic powerful urease producers. These organisms
inhabit the mucus adjacent to the gastric mucosa.
Important adaptive features improve survival of the organism in an acidic environment
include its shape and motility, its low oxygen needs, its adhesion molecules serving a feeding
role in certain gastric cells and urease production. Bacterial urease converts urea to ammonia
and bicarbonate, therefore neutralizing gastric acid and providing protection from a hostile
environment. Some of the lipopolysaccharides of the organism mimic the Lewis blood group
antigens structure. This molecular mimicry also helps the survival of H. pylori in the unfav‐
ourable gastric environment. [23]
H. pylori generates disease triggers, including urease, vacuolating cytotoxin, catalase and
lipopolysaccharide (LPS). Urease is a potent antigen inducing increased production of immu‐
noglobulin G and immunoglobulin A. Expression of vacuolating cytotoxin generating
inflammatory cytokines may be associated with more pronounced inflammation and marked
tendency of disease triggering.
The most important virulence factor in H. pylori infection is cytotoxin - associated antigen
(CagA). A person infected with CagA -negative strains is likely to develop chronic gastritis
and have little chance to develop peptic ulcer disease or gastric cancer.
On the other hand, infection with CagA -positive strains greatly increases the risk of peptic
ulcer and gastric cancer.  Movement of CagA protein into gastric epithelial  cells leads to
rearrangement  of  the  host  cytoskeleton,  alters  signalling  cell  and disturbs  the  cell  cycle
control. [24]
In children with H. pylori infection, who have peptic ulcer disease, in situ expression of CagA
is increased and may play an important role in the pathogenesis of peptic ulcer disease. [25]
The bacteria H. pylori localises in the stomach, induces inflammatory cytokines formation and
causes gastric inflammation. People with H. pylori gastritis associated with increased gastric
acid gastritis are prone to peptic ulcer disease. [26] In contrast, people infected with H. pylori
associated with corpus gastritis, with decreased gastric acid production are more prone to
developing gastric atrophy (intestinal metaplasia and gastric adenocarcinoma).
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The infection with H. pylori has been associated with iron deficiency anaemia. The two main
assumptions underlying this theory are iron sequestration because of antral H. pylori infection
and decrease of non- hemin iron absorption caused by hypochlorhydria.
H. pylori infection and its association with gastric malignancies have been well described in
several epidemiological studies. [27] However, the evolution from inflammation to cancer
remains unclear.
There exists a model describing the progressive evolution of H. pylori infection to hypochlo‐
rhydria, chronic gastritis, atrophic gastritis, dysplasia, intestinal metaplasia and gastric cancer.
[28, 29, 30, 31]
A newer hypothesis suggests that H. pylori infection may protect against self - inflammatory
diseases such as asthma or inflammatory bowel disease. For instance, epidemiological data
suggest that infection with Helicobacter pylori is less common in patients with inflammatory
bowel disease, which leads to research for defining potential mechanisms underlying these
clinical findings. [27]
10. Morbidity
Most H. pylori infected children are asymptomatic. Antral gastritis is the most common
manifestation in children. Duodenal and gastric ulcers may be associated with H. pylori
gastritis in adults, but is less common in children. The risk of gastric cancer, including non -
Hodgkin lymphoma (i.e. associated to the lymphoid tissue mucosa MALT]) and adenocarci‐
noma is increased in adults.[4]
The relationship between H. pylori gastritis and recurrent abdominal pain (RAP) is controver‐
sial. The incidence of H. pylori gastritis in patients with RAP is not significantly higher than
the incidence of H. pylori infection in the general population. Although certain studies have
shown an improvement in symptoms in children with RAP and Helicobacter pylori gastritis
after eradication therapy for H. pylori, data from a recent double-blind controlled trial have
not confirmed this finding. [32]
According to the North American Society for Paediatric Gastroenterology, Hepatology and
Nutrition no results were sufficiently reliable to support routine testing for H. pylori in children
with RAP. [33]
Data published so far highlight an association between H. pylori infection and gastrointestinal
symptoms in children, but no association has been found between RAP and H. pylori infection.
Conflicting evidence has been found however concerning the association of H. pylori infection
with epigastric pain. [34]
There are studies suggesting that H. pylori protects the human body from developing gastro‐
esophageal reflux disease, while others affirm a causal association between them. Analysis of
studies in conducted in adults has found no association between H. pylori eradication and
development of new cases of gastroesophageal reflux disease in dyspeptic patients. [35]
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According to a pediatric retrospective study, there was a significantly higher prevalence of
reflux esophagitis in H. pylori infected children. [36]
H. pylori infection was also associated with extraintestinal manifestations such as short stature,
immune thrombocytopenic purpura and migraine, with different levels of causation. [37, 38].
This infection is also associated with coronary diseases, iron-deficiency anemia and hepato‐
biliary diseases among others. [39, 40, 41, 42, 43, 44]
11. Dissemination (population category)
The predominance H. pylori infection is increased in black, Hispanic, Asian, and Native
American populations.
The infection with H. pylori affect more than a half of the world's population, which is acquired
almost always within the first 5 years of life [45]. In the developed world, the prevalence rates
vary from 1.2% to 12.2% [46-49]. In developing countries, the prevalence rates are much higher.
The serological prevalence rates of H. pylori were 45% among Indian children [40,51]. In Bolivia
and Alaska, at the age of 9 years, the seroprevalence was 70% and 69%, respectively [52]. The
seroprevalence in preschoolers in Brazil was found to be 69.7% [53]. An age-related increase
of the prevalence of H. pylori, irrespective of the economic state of the country, was observed
by several independent studies across the world [47-51, 54, 55].
In a study of Prof Dr Sibille Koletzko et al [15] was presented that during the first years of life
in both developing and industrialized countries the H. pylori infection is usually acquired.The
epidemiology of H. pylori infection in children, in Europe and North America has changed in
recent decades. In the northern and western European countries are founding low incidence
rates, resulting in prevalence far below 10% in children and adolescents. In contrast, the
infection is still common in certain geographic areas such as southern or eastern Europe,
Mexico, and certain immigrant populations from South America, Africa, and most Asian
countries, and aboriginal people in North America. The different prevalence of infection and
the corresponding effect on health care resources in industrialized compared with developing
countries require different recommendations with respect to testing and treating children.
These guidelines apply only to children living in Europe and North America, but not to those
living in other continents, particularly in developing countries with a high H. pylori infection
rate in children and adolescents and with limited resources for health care [15].
Infection rates are similar in men and women alike.
Many study present that less than 10% of children under 12 years of age are infected in
developed countries, but seropositivity increases with age, to a rate of 0.3-1% per year.
Seropositivity studies in developed countries in adults showed a prevalence of 30-50%.
In the US, estimated prevalence is 20% for people under 30 and 50% for persons over 60.
In  developing  countries,  prevalence  rates  are  much  higher.  H.  pylori  serological  preva‐
lence  rates  have  been  15% and 46% for  Gambian  children  under  20  months  and 40-60
months, respectively. [56]
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12. Laboratory methodology
An important study of Prof Dr Sibille Koletzko et al was presented by using the testing
guidelines recently provided by the European Society for Paediatric Gastroenterology
Hepatology and Nutrition (ESPGHAN) and the North American Society for Paediatric
Gastroenterology, Hepatology and Nutrition (NASPGHAN) for H. pylori infection in children
[15]. These recommendations are:
• The primary purpose of clinical investigation of gastrointestinal symptoms is to determine
the primary cause of the symptoms, and not the presence of H. pylori infection only.
• Diagnostic tests for H. pylori infection are not recommended in children with functional
abdominal pain. Currently, in the absence of ulcer disease, there is insufficient evidence to
justify a causal relationship between H. pylori gastritis and abdominal symptoms. Therefore,
cases of abdominal pain consistent with diagnostic criteria for functional pain should not
be investigated for H. pylori, unless upper endoscopy is conducted during diagnostic, in
search of some organic disease.
• In children with first-degree relatives with gastric cancer, H. pylori testing may be consid‐
ered.
• In children with refractory iron deficiency anaemia in whom other causes have been
excluded, H. pylori testing can be considered.
• There is insufficient evidence that H. pylori infection is causally linked with otitis media,
respiratory tract infections, periodontal diseases, food allergies, sudden infant death
syndrome, idiopathic thrombocytopenic purpura and short stature.
• To confirm eradication in children selected with disease complicated by peptic ulcer or
lymphoma and in children who remain symptomatic.
For diagnostic tests to be applied, the recommendations are as follows:
• For the diagnosis of H. pylori infection during esophagogastroduodenoscopy (EGD), it is
recommended to obtain gastric biopsy samples (antrum and corpus gastritis).
• It is recommended that the initial diagnosis of H. pylori infection rely on positive histopa‐
thology examination and a rapid urease positive test or a positive culture.
• The 13C - urea breath test (UBT) is a non-invasive test to determine successful eradication of
H. pylori.
• A positive enzyme immunoassay (ELISA) for the detection of H. pylori antigen in the stool
is a noninvasive test to determine whether H.pylori has been eradicated. Several methods
are available for detection of the H. pylori antigen in stool, such as the enzyme immunoassay
test (EIA) based on polyclonal or monoclonal antibodies and immunochromatographic tests
(the so-called rapid tests).
Stool tests are generally much more convenient in children than UBT. Neither storage of
evidence at room temperature for up to 5 days nor freezing them for months or even years
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appears to influence the accuracy of the stool tests. So far, only EIA based on monoclonal
antibodies has equalled UBT accuracy.
• Tests relying on antibody detection (IgG, IgA) against H. pylori in the blood serum, urine
and saliva are not viable for use in the clinic setting.
• Physicians are recommended to wait for at least 2 weeks after end of the proton pump
inhibitors (IPP) therapy and for 4 weeks after end of antibiotics before conducting biopsy
and non-invasive tests (UBT, stool test) for H. pylori.
It should be noted that these guidelines only apply to children in Europe and North America,
not in other continents, particularly developing countries, with a high rate of paediatric H.
pylori infection and limited health resources.
Another studies / tests
• Imaging studies are not useful in the diagnosis of H. pylori infection. They can be useful in
patients with complicated diseases (e.g., ulcer, gastric cancer, MALToma).
• Urea breath test: The patient ingests a test meal containing carbon-13 (13C) labelled urea,
which is a nonradioactive isotope. H. pylori urease activity produces 13C-labelled carbon
dioxide, detectable in the breath. A positive result confirms urease activity and H. pylori
infection. This is a highly specific test, sensitive in patients over 6 years of age. It is useful
to check eradication of H. pylori after treatment. Experience in children 5 years or younger,
in infants particularly, is relatively limited and needs further validation.
Detection of Helicobacter pylori
The procedure of choice for detecting gastritis, duodenitis and PUD in the paediatric popula‐
tion is upper endoscopy (EGD)
• EGD allows direct visualization of the mucosa, for locating the source of bleeding, to detect
H. pylori by biopsy, culture and cytology analysis and DNA testing using PCR.
• In addition, a rapid test based on detection of urease activity (a H. pylori highly specific
marker) may be performed. The test, called the Campylobacter test (CLO) allows diagnosis
of H. pylori infection within 24 hours.
• Two modified urea rapid test kits are currently available on the market and reported as
more accurate, with shorter reaction time and of better value for money than the CLO test.
• Endoscopy in children may reveal a nodular appearance in the gastric antrum resulting
from lymphoid hyperplasia [34]. Approximately 50% of affected children have displayed
endoscopic evidence of changes of H. pylori gastritis.
The appearance of an active ulcer is round or oval lesion in shape, the perforated base being
smooth and white, with a red and oedematous surrounding mucosa. In H. pylori infection, the
most common site for ulcer is the duodenal bulb.
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Biopsy obtained from the prepiloric antrum has the highest yield in H. pylori infection. Often,
tissue samples are also obtained from the body and the transition areas of the stomach,
especially when the patient has recently taken acid suppressing medications.
• Endoscopic biopsy is indicated for the following reasons:
• Histological examination of gastric tissue;
• Rapid urease test (e.g. CLO test)
• Culture of organisms;
• PCR test for identification of H. pylori DNA
• Histological findings include infiltration of a substantial number of plasma cells and
lymphocytes into the gastric mucosa and Giemsa, Diff-Quick visible bodies or haematoxylin
and eosin. Sensitive colouring of a small number of bacteria is possible with a silver staining
method such as Genta or Warthin-Starry.
Stages
• Multiple stages in the progression of the disease are well described in the literature, although
no stages system for H. pylori infection has been established.
• The first step is chronic gastritis, followed by a second step, atrophic gastritis. The third step
is intestinal metaplasia, which can evolve to dysplasia. The last step in this process is gastric
adenocarcinoma.
• This is a very slow process (which may take decades, for example), and can stop at any step
because gastric cancer probably requires several other factors to grow, not just H. pylori
infection.
Treatment measures of Helicobacter pylori infection
Let us mention the new treatment rules recommended for the following patient groups [15]:
• In the presence of H. pylori-positive PUD, eradication of the microorganism is recommend‐
ed.
• On detection of H. pylori infection by biopsy based methods in the absence of PUD, H.
pylori treatment may be considered. The decision to treat H. pylori associated gastritis
without duodenal or gastric ulcer is subject to the clinician’s judgment and deliberation is
undertaken with the patient and family, taking into account potential risks and benefits of
treatment for the patient.
• In H. pylori infected children, whose next of kin suffer from gastric cancer, treatment can be
offered.
• The "test - and-treat" strategy is not recommended for children. The main purpose of the
tests is to diagnose the cause of the clinical symptoms.
Currently practiced therapeutic approach takes the following into account:
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• H. pylori acquired resistance to antibiotics, which requires bacterial strain susceptibility
testing to a certain class of antibiotics in geographic areas where resistance is seen in
encountered in a percentage of patients;
• Success rate in eradication of infection is directly dependent on the dose and duration of
medication administered. In practice however, this is less apparent because of lower
compliance in long cures and because of adverse effects (vomiting, nausea, malaise) in high
doses;
• Bismuth (Bi3+) salts preparations are effective but difficult to accept by children because of
their bad taste;
• Therapeutic management aims not at eradication of H. pylori infection only but also at
resolution of the pathology is determines (gastritis, reflux, dyspepsia etc.) and therefore
triple therapy may be associated with prokinetics and hygienic-dietary regime to spare
digestion;
• Unwanted side effects of the antibiotics cure can be reduced by administration of probiotic
preparations that restore normal intestinal flora.
The following treatments should be implemented [15]:
• First line eradication regimens are: triple therapy with a PPI + amoxicillin + imidazole, or
PPI + amoxicillin + clarithromycin + amoxicillin or bismuth salts + imidazole or sequential
therapy. Sequential therapy involves dual therapy with a PPI and amoxicillin for 5 days,
successively followed by five days of triple therapy (a PPI with clarithromycin and metro‐
nidazole / tinidazole). In fact, this scheme may be considered as quadruple therapy provided
in a sequential manner. It is speculated that the initial use of amoxicillin reduces bacterial
load and provides protection against resistance to clarithromycin.
• Clarithromycin antibiotic susceptibility testing is recommended prior to clarithromycin
triple therapy in areas / populations definable as clarithromycin highly resistant (> 20%) to
H. pylori.
• The recommended period for triple therapy is 7-14 days. Costs, compliance and adverse
effects should be taken into account.
• A reliable non-invasive test for eradication is recommended at least 4-8 weeks after treat‐
ment.
In cases of treatment failure, the following 3 options are recommended:
• EGD with culture and sensitivity tests, including alternative antibiotics if not performed
prior to standard treatment.
• Insitu fluorescence hybridization (FISH) on paraffin-embedded biopsies, if clarithromycin
susceptibility testing was not performed before standard therapy.
• Therapy changing by addition of an antibiotic, using various antibiotics, as well as addition
of bismuth, and / or increase of the dose and / or treatment duration.
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If not possible to perform a primary culture, the following regimens are suggested as second-
line or rescue therapy [15]:
• Quadruple therapy consists of metronidazole + amoxicillin + PPI + bismuth. In most
guidelines, quadruple therapy is the recommended second-line therapy, but this is a
complicated regimen to administer. In addition, bismuth salts are not universally available.
• Triple therapy consists of PPI + levofloxacin (moxifloxacin) + amoxicillin. Regimen evalua‐
tion using fluoroquinolones, including levofloxacin, as second-line therapy in children is
limited. In studies in adults, the treatment seems to be effective.
Although studies during ideal therapy duration for second-line treatment are not conclusive,
a longer treatment duration is recommended, up to 14 days.
Other procedures
• Surgical procedures are rarely needed in treatment of patients with H. pylori infection.
However, the ulcer, surgery may be required for certain complications unresponsive to
medical treatment, including difficult to treat abdominal pain, gastric outlet obstruction,
perforation and severe bleeding.
• Consultations pediatric gastroenterologists: For evaluation, endoscopy and biopsy to
confirm Helicobacter pylori infection and rule out other causes for abdominal pain or
bleeding;
• Surgeon - For intervention in patients with severe or intractable pain or bleeding or patients
with intestinal perforation or obstruction of the gastro-intestinal tract;
• Radiologist - For patients requiring upper gastrointestinal imaging with contrast-enhanced
studies.
Hygienic-dietary regime
A sparing digestive hygienic-dietary regime is recommended, including meals and snacks
every 3-4 hours with correct chewing and avoidance of food aggressors. Foods such as fruit
juices and certain dairy products may have a modest bacteriostatic effect on H. pylori. Active
principles (sulforaphane and indole-3-carbinol) of the Brassicaceae family are also included
here.
• Two randomized, placebo-controlled studies have evaluated the effect of probiotic food as
an adjunct to standard triple therapy for eradication of H. pylori infection in children and
have had conflicting results [58, 59].
• In a recent prospective study in adults, it was suggested that the addition of vitamin C to a
regimen of H. pylori with amoxicillin, metronidazole, and bismuth can significantly increase
the H. pylori eradication rate [60].
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13. Medicines used in H. pylori eradication therapy [61-73]
Antibiotics, beta-lactamases
Beta-lactamases used to treat H. pylori infected patients are stable in an acidic environment,
binding to proteins in bacterial cell walls, inducing direct lysis in the wall, and inhibiting cell
wall synthesis.
Amoxicillin (Amoxil®, Polymox®, Trimox®, Wymox®)
Bacterially active against Helicobacter pylori. Available as GTT 50mg/ml; susp.125, 200, 250, or
400mg/5ml; caps 250 and 500 mg chewable tablets and 125, 200, 250, or 400mg.
Antibiotics, macrolides
Macrolides used to treat H. pylori infection are stable in the stomach, entering the bacterial cell,
binding to receptors on the ribosomal subunits and inhibiting bacterial protein synthesis.
Clarithromycin (Biaxin®, Fromilid®)
This displays bactericidal activity against H. pylori antimicrobial spectrum similar to that of
erythromycin but stable in acid and with fewer adverse gastrointestinal effects. Available as
125 or 250mg/5ml granules for suspension and 250 or 500 mg film-coated tablets.
Antibiotics, antiprotozoans
Used in the treatment of H. pylori infected patients, this antibiotic generates intracellular
products affecting bacterial DNA.
Metronidazole (Flagyl®, Protostat®)
Metronidazole diffuses well into all tissues, is stable in an acidic environment, and provides
bactericidal activity against H. pylori. Available as ex tempore 50 sau100mg/5ml suspension,
250 or 500mg tablets and 375 mg capsules.
Antibiotics, tetracyclines
Tetracyclines bind to ribosomal subunits and inhibit protein synthesis of susceptible bacteria.
Use in paediatric patients should be limited in cases where other antibiotic regimens fail.
Tetracycline hydrochloridum (Achromycin®, Sumycin®, Terramycin®)
Bacteriostatic but may be bactericidal in high concentrations. Also available as 250 or 500mg
tablets, 100, 250, or 500 mg capsules, and 125mg/5ml suspension.
H2 receptor antagonists
H2 receptors are located on acid-producing parietal cells. Blocking the action of the histamine
suppresses gastric acid secretion.
Ranitidine (ranitidinum) or Famotidine (famotidinum)
H2 antagonists prescribed for 8 weeks, when most H. pylori associated ulcers are cured. H2
blockers have no antibacterial effect, therefore antibiotics should be used to eradicate H.
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pylori. Available as 15mg/ml syrup, 75, 150, or 300 mg tablets, as well as effervescent tablets
150mg.
Proton Pump Inhibitors
This class of medicinal products includes acid inhibitors more potent than H2 receptor
antagonists; they block the secretion of gastric acid proton pump (Na + / H +-ATP-ase), the
final common path of the secretion. This class is recommended as part of a regimen of
medications in symptomatic patients with H. pylori infection. Similar to H2-receptor blocking
treatment, proton pump inhibitor (PPI) treatment only does not eliminate the H. pylori
infection, but increases the bacteriostatic activity against H. pylori.
Examples of trade names depending on the active substance:
• Omeprazole: Omeprazole®, Prilosec®, Omez®, Omeran®, Ulto® (available within 10, 20 or 40
mg per tablet)
• Esomeprazole: Nexium®, Emanera®, Helide®, Esomeprazole Sandoz® (20 or 40 mg)
• Pantoprazole: Controlo®, Nolpaza® (20 or 40 mg per tablet)
• Lansoprazol: Prevacid®, Lanzul® 30mg
Proton Pump Inhibitors are potent gastric acid blockers. For best effectiveness, to be admin‐
istered before the first meal of the day. Enteric film-coated granules in capsules, they ensure
adequate bioavailability. For children unable to swallow whole capsules, the grains are opened
and put in acid substances (e.g. apple juice), which is preferable to administer to the lower
bioavailability suspension. Available as 10 or 20 mg SR capsules and granules for suspension
per os 20 or 40 mg/package.
Lansoprazole (Prevacid®)
Potent gastric acid blocker. Best administered just before the first meal of the day. Enteric film-
coated granules in capsules, ensuring adequate bioavailability. For children unable to swallow
the intact capsules, granules are placed in acid substances (e.g., applesauce or apple juice),
preferable to the administration of lower bioavailable suspension. Available as capsules with
15 or 30 mg retard release and 15 mg or 30mg/package granules for suspension per os.[75-85]
Bismuth
Bismuth subsalicylate and bismuth subcitrate have complementary effects with most antimi‐
crobials. Bismuth disrupts enzymatic activity in bacterial cell walls. Bismuth is particularly
effective in the lysis of the cell wall of the microorganism when close to the gastric epithelium
and relatively inaccessible to most antimicrobial agents.
Bismuth subsalicylate (Pepto-Bismol®)
These lyse bacterial cell walls, prevent microorganism adhesion to epithelium and inhibit
urease.
Available as 262 mg chewable tablets (bismuth subsalicylate) and 262mg or 525mg/15ml
solution.
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Bismuth subcitrate (De - Nol®) acts similarly. The patient should be warned against normal
black stools during the treatment administration.
Patient care
In children with H. pylori and complications of the peptic ulcer disease (PUD), including
bleeding, severe pain, perforation, or obstruction, care must include the following [86-106]:
• Attention to the airway, breathing and circulatory status
• Monitoring of fluid resuscitation, with consideration for transfusion
• Careful nasogastric lavage in stabilization of upper gastro-intestinal bleeding
• Antacid therapy with proton pump inhibitors (PPIs), maximum dosage
• Appropriate consultation with specialists in endoscopy or other procedures
• In children with stress-induced PUD, the treatment of the severe disease or traumatic injury
• additional outpatient care includes monitoring the patient's symptoms, assessment of
patient tolerance to treatment regimen, and follow-up tests to confirm the effectiveness of
the treatment. The tests should be conducted at least 6 weeks and preferably 3 months after
treatment.
Outpatient treatment of patients
• Patients should avoid all irritating drugs, including anti-inflammatory drugs (NSAIDs),
aspirin, and preparations with corticosteroid
• It is necessary for the treatment of iron deficiency anaemia.
Prophylactic measures
• The transmission mode of H. pylori infection is not fully understood.
• Data from epidemiological studies suggest that the following measures may be helpful to
reduce transmission:
• Policies supporting improvement of living conditions, particularly in developing countries;
• For all patients with chronic symptoms of the gastro-intestinal tract, appropriate reference
for definitive diagnosis and treatment, which may also help to prevent exposure of family
members and close contacts.[103-111]
• H. pylori infection vaccines: several studies performed with urease -based vaccines have
shown limited efficacy in humans. Vaccines based on recombinant CagA-VacA-0AP
proteins display good immunogenicity of CagA - based cow - 0AP good immunogenicity
and safety profile in phase I, but no subsequent efficacy studies have been reported. No
further results from clinical trials on H. pylori vaccines have been reported in recent years.
Currently, there is no authorised anti - H. pylori vaccine [74].
H. pylori Complications
• PUD - perforation, gastrointestinal bleeding
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• Iron deficiency anaemia
• Malignancies of:- The gastric mucosa associated to lymphoid tissue (MALT) - Adenocarci‐
noma of the gastric corpus, and the antrum
• Gastric outlet obstruction
• Increased sensitivity to enteric infections such as salmonella and giardiasis because of H.
pylori-induced hypochlorhydria [92, 96]
14. Prospects study
1. Prospects for the eradication of H. pylori infection with multidrug therapy are good, with
up to 95% reported efficacy rates.
2. Treatment is often unsuccessful because of lack of patient compliance and antibiotic
resistance.
3. When cleaning is completed, long-term reinfection rates are low. Among children living
in developing countries or among families with infected members, reinfection rates may
be increased.
4. In this moment, the nature of H. pylori infection transmission is not fully understood.
Therefore, the ability to implement appropriate preventive measures to control the
infection is limited.
5. The theory concerning H. pylori person-to-person transmission, supported by data from
epidemiological studies, may prove useful in promoting policies to improve the living
and hygiene conditions and reduce crowdedness.
6. The true effect of educational authorities to reduce transmission of H. pylori in the patient's
family (e.g., teaching children about proper hygiene and toilet practices) is unknown.
However, such efforts may be part of a sensible approach to reducing the transmission of
all infection pathogens in the infection of the gastrointestinal tract [109-111].
15. Conclusions
The infection with H. pylori is a common problem in pediatric practice and its origin is related
with poor socio-econo-mic conditions. Only a small number of children with well-defined
clinical syndromes are benefited at present from testing and treatment.
The first line eradication regimens are triple therapy with a PPI, amoxicillin and imidazole, or
PPI, amoxicillin, clarithromycin and amoxicillin or bismuth salts and imidazole or sequential
therapy.
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Each country may need to be adapted the recommendations guidelines to national health care
systems, because certain tests or treatment regimens may not be available and /or reimbursed
by health insurance programs.
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